Paclitaxel 化学構造
分子量: 853.91

高品質保証

カスタマーフィードバック(2)

Quality Control & MSDS

製品説明

  • Compare Microtubule Associated Inhibitors
    Microtubule Associated製品生物活性の比較
  • 研究分野

製品の説明

生物活性

製品説明 パクリタキセル(タキソール、Onxol、Nov-Onxol)は、人間の内皮細胞の0.1pMのIC50による微小管ポリマー安定剤です。
ターゲット Microtubule (human endothelial cells)
IC50 0.1 pM [1]
In vitro試験 Paclitaxel inhibits non-endothelial type human cells at 104 - to 105 -fold higher concentrations, with IC50 of 1 nM-10 nM. The selectivity of Paclitaxel inhibition of cell proliferation is also species specific, as mouse ECs are not sensitive to Paclitaxel at ultra low concentrations. Inhibition of human ECs by Paclitaxel at ultra low concentrations does not affect the cellular microtubule structure, and the treated cells do not show G2/M cell cycle arrest and apoptosis, suggesting a novel but as yet unidentified mechanism of action. In an in vitro angiogenesis assay, Paclitaxel at ultra low concentrations blocks human ECs from forming sprouts and tubes in the three-dimensional fibrin matrix. [1] In the presence of SMF, the efficient concentration of Paclitaxel on K562 cells is decreased from 50 to 10 ng/mL. The cell cycle arrest effect of Paclitaxel with or without SMF on K562 cells is correlated with DNA damage. [2] Paclitaxel alone causes a time-dependent inhibition of CDK1 in four cell lines including A549 cells, H358, H1395 cells and H1666 cells. [3]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
TE-15 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHWPJZiUUN3ME2wMlAxODJ6NzFOwG0> MUfTRW5ITVJ?
LC-2-ad NHfMfIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\6c4pKSzVyPUCuNFAxOzF5IN88US=> MlHHV2FPT0WU
RL95-2 NH;XRZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGm3NlJKSzVyPUCuNFAxPjZ6IN88US=> Mmi0V2FPT0WU
MZ1-PC MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3ixNmlEPTB;MD6wNFA4OjlizszN MlHHV2FPT0WU
TE-8 NEK3[|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrtc5hKSzVyPUCuNFAyOTdizszN NGTX[YNUSU6JRWK=
SW954 M2iyZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTBwMECxNVkh|ryP NH3IdG5USU6JRWK=
TE-11 NVX1ZYRTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnMTWM2OD1yLkCwNVI{KM7:TR?= NWflZ|hCW0GQR1XS
PSN1 NWnMWY84T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLEfVdIUUN3ME2wMlAxOTNizszN NFHreWNUSU6JRWK=
MOLT-4 MnzMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4r5XWlEPTB;MD6wNFE1QSEQvF2= NGK1Z2tUSU6JRWK=
697 NWrNVW4zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDhTWM2OD1yLkCwNVUh|ryP NH7vT3NUSU6JRWK=
ETK-1 MkjzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVr2dHg6UUN3ME2wMlAxOTV{IN88US=> MnexV2FPT0WU
TE-10 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfDdIpGUUN3ME2wMlAxOTV2IN88US=> NFrmSFNUSU6JRWK=
HUTU-80 NYnQPVZvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;xd|ZGUUN3ME2wMlAxOTZ6IN88US=> NXHFd5VvW0GQR1XS
NTERA-S-cl-D1 NFzp[HBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;KTWM2OD1yLkCwNlA6KM7:TR?= NVjUdnVZW0GQR1XS
MFH-ino NGPKSGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmm3TWM2OD1yLkCwNlY5KM7:TR?= NH7rZmhUSU6JRWK=
IA-LM NXz6[G1uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTBwMECyPEDPxE1? NFXGfJhUSU6JRWK=
MC116 NVn0bYpFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTBwMECyPFkh|ryP MWPTRW5ITVJ?
RKO NV[5RXo1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\oTHZoUUN3ME2wMlAxOjl6IN88US=> M{LYW3NCVkeHUh?=
MRK-nu-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTLRpRKSzVyPUCuNFAzQTlizszN MlPaV2FPT0WU
VA-ES-BJ NIjBWIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPLTWM2OD1yLkCwN{DPxE1? MnPQV2FPT0WU
KALS-1 M3HXbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfKTVBKSzVyPUCuNFA{ODhizszN MnvtV2FPT0WU
BB30-HNC NYHnb2xbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTBwMECzNVQh|ryP M4LqcXNCVkeHUh?=
ACN MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDiW4VbUUN3ME2wMlAxOzF4IN88US=> NEDFVGFUSU6JRWK=
TE-9 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjpNm9KSzVyPUCuNFA{OjZizszN M3XEenNCVkeHUh?=
SIG-M5 MlnrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zmO2lEPTB;MD6wNFMzPyEQvF2= M4PBfHNCVkeHUh?=
no-10 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUftbZN[UUN3ME2wMlAxOzZ{IN88US=> MlLpV2FPT0WU
EW-1 MoXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDSTWM2OD1yLkCwN|cyKM7:TR?= MmTXV2FPT0WU
SK-LMS-1 NX\SeGd6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;E[mlEPTB;MD6wNFQxOSEQvF2= NY\XTXBSW0GQR1XS
GT3TKB M2j3eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17SUmlEPTB;MD6wNFQ{PCEQvF2= MVfTRW5ITVJ?
ES4 NF70SI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7BSohKSzVyPUCuNFA1PDlizszN NVOzXWQ5W0GQR1XS
IMR-5 NV7TNnROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PuU2lEPTB;MD6wNFQ2KM7:TR?= NFroWGNUSU6JRWK=
NCI-H1648 NH7GclhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTBwMEC0Olkh|ryP MVfTRW5ITVJ?
MV-4-11 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITlN2pKSzVyPUCuNFA1PzVizszN M1jKT3NCVkeHUh?=
SK-UT-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTBwMEC0PEDPxE1? M4nqZnNCVkeHUh?=
NB13 NYnlU5FGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXuTWM2OD1yLkCwOFkyKM7:TR?= MUDTRW5ITVJ?
DJM-1 M4OycWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWW4OmN[UUN3ME2wMlAxPTNizszN MnnkV2FPT0WU
ES8 NWixb5RDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7vZXlWUUN3ME2wMlAxPTN6IN88US=> M2WwNXNCVkeHUh?=
TE-6 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4T1WWlEPTB;MD6wNFU4KM7:TR?= NYjSWoZDW0GQR1XS
KS-1 NFvZXoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;QTWM2OD1yLkCwOVgzKM7:TR?= NYLQ[WhDW0GQR1XS
TE-1 MkPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWK4c5BNUUN3ME2wMlAxPjB4IN88US=> MoTiV2FPT0WU
ATN-1 MmX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnK[YZKSzVyPUCuNFA3ODlizszN MXjTRW5ITVJ?
A4-Fuk NWfCUlZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTPcmRKSzVyPUCuNFA3OTFizszN NXjqNXM3W0GQR1XS
ALL-PO NIOzdJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkT1TWM2OD1yLkCwOlMh|ryP MlzQV2FPT0WU
BE-13 NF;Qco9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nNXWlEPTB;MD6wNFY{PiEQvF2= MUDTRW5ITVJ?
KM12 M1nw[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXkeZJiUUN3ME2wMlAxPjN5IN88US=> M1r6[HNCVkeHUh?=
NOS-1 M3TsVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HVbGlEPTB;MD6wNFY2KM7:TR?= NX;Zfm41W0GQR1XS
SW962 MofDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHyxbWtKSzVyPUCuNFA3PjJizszN NHKzUnNUSU6JRWK=
OCUB-M MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HmTmlEPTB;MD6wNFY3OiEQvF2= M1rvRXNCVkeHUh?=
NCI-H510A M3XUNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnT0TWM2OD1yLkCwOlY2KM7:TR?= NXvUPYl5W0GQR1XS
EW-16 M2rDdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXQTWM2OD1yLkCwOlk1KM7:TR?= M3niVHNCVkeHUh?=
KGN NUC0S3NKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTBwMEC3NVIh|ryP NF71PWFUSU6JRWK=
LS-411N MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTHTWM2OD1yLkCwO|E4KM7:TR?= MXLTRW5ITVJ?
Becker NHO2fW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYK4NZkxUUN3ME2wMlAxPzJizszN MkDlV2FPT0WU
HC-1 MkXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn[1TWM2OD1yLkCwO|IyKM7:TR?= NEHjcpZUSU6JRWK=
CESS M17GR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTBwMEC3N|ch|ryP NYDwVWtRW0GQR1XS
KURAMOCHI MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDjTWM2OD1yLkCwO|Q5KM7:TR?= NGm2XG9USU6JRWK=
TGBC24TKB M2XG[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTBwMEC3OVIh|ryP MofUV2FPT0WU
SW982 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTBwMEC3OlYh|ryP NFPE[ppUSU6JRWK=
HCE-4 NX\DTJB{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nYU2lEPTB;MD6wNFc3PyEQvF2= NGfnWoZUSU6JRWK=
LOUCY Mn\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYP0fZQ6UUN3ME2wMlAxPzd3IN88US=> NHL0UYNUSU6JRWK=
8-MG-BA MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoH5TWM2OD1yLkCwO|k3KM7:TR?= MlzxV2FPT0WU
HT-144 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1i4e2lEPTB;MD6wNFgh|ryP MXTTRW5ITVJ?
LXF-289 MmC4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTBwMEC4NVgh|ryP M2Oye3NCVkeHUh?=
RS4-11 NXTu[nFET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjL[ZpUUUN3ME2wMlAxQDN4IN88US=> MlzqV2FPT0WU
DEL MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jDVGlEPTB;MD6wNFg1PSEQvF2= NUniN4N7W0GQR1XS
OCI-AML2 M4TYXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{i2R2lEPTB;MD6wNFg2OiEQvF2= NXrsXII5W0GQR1XS
CCRF-CEM MoG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTBwMEC4O|Eh|ryP MX\TRW5ITVJ?
A388 M2DONmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorzTWM2OD1yLkCwPFc1KM7:TR?= MlT5V2FPT0WU
KNS-42 NITa[oxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXETWM2OD1yLkCwPFkyKM7:TR?= NF;3SmtUSU6JRWK=
OVCAR-4 M1nRWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\nSWdKSzVyPUCuNFA6ODRizszN MVrTRW5ITVJ?
NCI-H1355 NYHWe5VCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFS3SG1KSzVyPUCuNFA6OTRizszN NVHjTndGW0GQR1XS
BL-70 Mo\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M321fGlEPTB;MD6wNFk{KM7:TR?= MXnTRW5ITVJ?
BL-41 NU\WZmNLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXf4ZXhRUUN3ME2wMlAxQTN2IN88US=> NWexb5puW0GQR1XS
A101D NWr1U3BjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7lUVhKSzVyPUCuNFA6PiEQvF2= NU\jeFBmW0GQR1XS
HL-60 NHL6VXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTBwMEC5OlYh|ryP MmG0V2FPT0WU
COR-L279 NUXROm0zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4[2VWlEPTB;MD6wNFk6QSEQvF2= NXjETFZrW0GQR1XS
NCI-SNU-16 M2rz[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2iwWWlEPTB;MD6wNVAxQCEQvF2= MXLTRW5ITVJ?
Calu-6 MnfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTBwMEGwNVIh|ryP NIn1[3JUSU6JRWK=
SR MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzUTWM2OD1yLkCxNFI3KM7:TR?= MmHjV2FPT0WU
QIMR-WIL MnXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PZfmlEPTB;MD6wNVA{OyEQvF2= NVvzdFVHW0GQR1XS
LB647-SCLC NGPxXmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlr2TWM2OD1yLkCxNFUyKM7:TR?= MYfTRW5ITVJ?
RPMI-8226 NIjoPItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmj5TWM2OD1yLkCxNVAzKM7:TR?= Mmr4V2FPT0WU
SK-PN-DW MnPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\kTWM2OD1yLkCxNVEzKM7:TR?= M3zRfXNCVkeHUh?=
SF268 M3S5bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XieGlEPTB;MD6wNVE2OSEQvF2= NED4OJNUSU6JRWK=
HD-MY-Z M{TaWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvNTWM2OD1yLkCxNVY{KM7:TR?= NFnnWZlUSU6JRWK=
DOHH-2 NF3Q[WRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTm[5Q4UUN3ME2wMlAyOjB|IN88US=> MYfTRW5ITVJ?
SCC-3 NHjZelRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLSZZBKSzVyPUCuNFEzODRizszN MWnTRW5ITVJ?
ST486 NIXKfnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTBwMEGyNFQh|ryP NXjoXJhkW0GQR1XS
NALM-6 MofGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYruTWRjUUN3ME2wMlAyOjF2IN88US=> NYfOW4FlW0GQR1XS
NCI-H1436 NXS5R5JoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPCeXJ{UUN3ME2wMlAyOjNzIN88US=> MmnEV2FPT0WU
KE-37 MkHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTBwMEGyN|Qh|ryP NEnaeVZUSU6JRWK=
RPMI-8402 NW\mVW8{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTtcHg1UUN3ME2wMlAyOjV4IN88US=> NGDqWJlUSU6JRWK=
RXF393 NGXCfIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTBwMEGyOVch|ryP NUXFfY1VW0GQR1XS
KARPAS-45 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnMeIFKSzVyPUCuNFEzPyEQvF2= MoG3V2FPT0WU
HOP-62 MoDJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;ZTWM2OD1yLkCxNlc3KM7:TR?= NYLGOYhIW0GQR1XS
ES1 NV3CXGl1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnL4TWM2OD1yLkCxNlg5KM7:TR?= MmThV2FPT0WU
L-363 M3HlS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\TelZKSzVyPUCuNFE{PTFizszN M{fZZ3NCVkeHUh?=
GI-1 NY\OSJFKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTBwMEGzO|Mh|ryP NHL1ToNUSU6JRWK=
CTV-1 NXLl[nl{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTBwMEG0O|gh|ryP MmLoV2FPT0WU
TE-5 MofRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTBwMEG0PVYh|ryP NHnWOJFUSU6JRWK=
SNU-C2B Mkm5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYGwU5I1UUN3ME2wMlAyPDl4IN88US=> Mlm3V2FPT0WU
K-562 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vRVWlEPTB;MD6wNVUyPiEQvF2= NFTaeXJUSU6JRWK=
SNB75 NETFfYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLKWo5KSzVyPUCuNFE2PCEQvF2= M{XjbnNCVkeHUh?=
MOLT-13 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPXSmdKSzVyPUCuNFE3OzdizszN NH33bGNUSU6JRWK=
LS-123 NXznZ3JsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XiWGlEPTB;MD6wNVY3PCEQvF2= MofVV2FPT0WU
NCI-SNU-5 NHmxepJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2m1fWlEPTB;MD6wNVcxOSEQvF2= NIqyc3lUSU6JRWK=
Daudi NF24[4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVz1S2dzUUN3ME2wMlAyPzB6IN88US=> NGiydI1USU6JRWK=
A253 M{G1S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTHRmdMUUN3ME2wMlAyPzN6IN88US=> M2exZXNCVkeHUh?=
TGBC1TKB M1PMfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTBwMEG3OVIh|ryP MkXtV2FPT0WU
SJSA-1 NX25[5FPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPWTWM2OD1yLkCxO|Y4KM7:TR?= MVzTRW5ITVJ?
NCCIT M{jm[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HPc2lEPTB;MD6wNVc3QSEQvF2= MnTUV2FPT0WU
NCI-H69 M3;OcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVj0WGxwUUN3ME2wMlAyPzd6IN88US=> M2LkNXNCVkeHUh?=
SH-4 NXzQV291T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLnTWM2OD1yLkCxPFk2KM7:TR?= NXfWToVqW0GQR1XS
HCC1187 M{T1emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWW4SlZFUUN3ME2wMlAyQTJ2IN88US=> MoXsV2FPT0WU
HCC1599 NHjGPJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLJTWM2OD1yLkCyNFIh|ryP MnLyV2FPT0WU
ONS-76 NETiSmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTBwMEKwN|Yh|ryP NEPoNXZUSU6JRWK=
KU812 NF;SR5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XMdGlEPTB;MD6wNlA{QSEQvF2= MlHzV2FPT0WU
ML-2 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPSTWM2OD1yLkCyNFQ4KM7:TR?= MmDpV2FPT0WU
HCE-T MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTVcZVKSzVyPUCuNFIxQTJizszN NXrMN4FMW0GQR1XS
NCI-H446 MlqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH21RWlKSzVyPUCuNFIyOTJizszN NWjhN3FlW0GQR1XS
RPMI-6666 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkH0TWM2OD1yLkCyNVQ6KM7:TR?= NFjHSG1USU6JRWK=
MOLT-16 M3rpT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2i3fmlEPTB;MD6wNlE2OyEQvF2= M3HFXnNCVkeHUh?=
JiyoyeP-2003 MkfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTBwMEKxO|Yh|ryP MUPTRW5ITVJ?
MHH-PREB-1 NHryVZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTBwMEKxPVEh|ryP MVPTRW5ITVJ?
MC-CAR M1K5PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTBwMEKzNlYh|ryP NVS1c4UzW0GQR1XS
BC-3 MmrRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFL0dY9KSzVyPUCuNFI{PDRizszN MYrTRW5ITVJ?
KINGS-1 MmPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTBwMEKzOVUh|ryP NFW5WpFUSU6JRWK=
PF-382 M1TOUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTBwMEKzO|gh|ryP MVHTRW5ITVJ?
J-RT3-T3-5 NVHHVHpFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2L3TmlEPTB;MD6wNlM5OyEQvF2= M4\vVnNCVkeHUh?=
SF539 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\WO4E3UUN3ME2wMlAzPDBzIN88US=> NIrST|dUSU6JRWK=
LB831-BLC NV3KXpBbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXi4PXU4UUN3ME2wMlAzPDh3IN88US=> MY\TRW5ITVJ?
DMS-114 MkTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoOyTWM2OD1yLkCyOVAzKM7:TR?= MVnTRW5ITVJ?
LB1047-RCC M3Tn[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnkO4FQUUN3ME2wMlAzPTFizszN NHfHWJBUSU6JRWK=
LB771-HNC MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1qxd2lEPTB;MD6wNlU{PCEQvF2= NFrKVXNUSU6JRWK=
BB65-RCC MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTGTWM2OD1yLkCyOVM1KM7:TR?= MVrTRW5ITVJ?
BV-173 MofiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrnXmlKSzVyPUCuNFI2PTRizszN MXrTRW5ITVJ?
ARH-77 NYC2[XZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml[0TWM2OD1yLkCyOlAyKM7:TR?= NI\ISppUSU6JRWK=
IST-MEL1 M17BOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTBwMEK2NlMh|ryP NXryOYtnW0GQR1XS
NB1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTBwMEK2PFch|ryP M17xT3NCVkeHUh?=
EoL-1-cell NFH3RplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTBwMEK2PFgh|ryP NGrDTplUSU6JRWK=
KY821 MoPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTBwMEK2PVch|ryP MnzhV2FPT0WU
CMK M2nYNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUC2fG44UUN3ME2wMlAzPzN2IN88US=> M{XkfXNCVkeHUh?=
NCI-H2126 NYnrS3g6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYi5[5VwUUN3ME2wMlAzPzZ6IN88US=> Mn3kV2FPT0WU
NCI-H526 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTBwMEK4PVEh|ryP MYXTRW5ITVJ?
COLO-684 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPRTWM2OD1yLkCyPVA5KM7:TR?= M3zy[3NCVkeHUh?=
NCI-H747 MorRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnmwTWM2OD1yLkCyPVM{KM7:TR?= MnrFV2FPT0WU
JAR MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTBwMEK5OFYh|ryP NVvROmZSW0GQR1XS
MEG-01 NGTVXohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLPTWM2OD1yLkCyPVc5KM7:TR?= M2HqVnNCVkeHUh?=
MONO-MAC-6 MkLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVP5V|h[UUN3ME2wMlA{ODJ|IN88US=> NH:2fIhUSU6JRWK=
IST-SL1 NXLYdHppT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnLTWM2OD1yLkCzNFQzKM7:TR?= MYjTRW5ITVJ?
CPC-N MlX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXzVJoxUUN3ME2wMlA{ODd7IN88US=> MkH4V2FPT0WU
NCI-H1963 Mk\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoK4TWM2OD1yLkCzNVMyKM7:TR?= Mki5V2FPT0WU
K052 M322dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfzUGlKSzVyPUCuNFMzPDdizszN MlTzV2FPT0WU
KM-H2 NHX5N4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1juSWlEPTB;MD6wN|MxPyEQvF2= M{DxdHNCVkeHUh?=
TE-12 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXH3[WNbUUN3ME2wMlA{OzB7IN88US=> M1ntWnNCVkeHUh?=
TK10 M{GyTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\6PJBKSzVyPUCuNFM{PTZizszN M4HrUXNCVkeHUh?=
NMC-G1 MoDkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELHeXZKSzVyPUCuNFM1PTJizszN MWTTRW5ITVJ?
no-11 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjzWY5FUUN3ME2wMlA{PDd6IN88US=> Ml3mV2FPT0WU
NCI-H524 Mn25S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXVTWM2OD1yLkCzOVI6KM7:TR?= MkXDV2FPT0WU
MHH-CALL-2 MlXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7hOm1KSzVyPUCuNFM2PjJizszN NYHiPWVxW0GQR1XS
GB-1 NXXJSnVHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF63do5KSzVyPUCuNFM3KM7:TR?= M{j6V3NCVkeHUh?=
OPM-2 MmfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIr0PZJKSzVyPUCuNFM3PzNizszN NGfoVYNUSU6JRWK=
RH-1 NGi3[lFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\nOIN{UUN3ME2wMlA{QDF7IN88US=> NGi2cWdUSU6JRWK=
NCI-H64 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjhbnRvUUN3ME2wMlA{QDV5IN88US=> M1eybnNCVkeHUh?=
EVSA-T MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;C[oFKSzVyPUCuNFM6OjNizszN NH;XPVdUSU6JRWK=
KARPAS-299 MmTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3u5NmlEPTB;MD6wN|k5KM7:TR?= M1XZcXNCVkeHUh?=
MZ7-mel NXPTXXZOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DHVWlEPTB;MD6wOFA1KM7:TR?= MlTGV2FPT0WU
LB373-MEL-D Ml7IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrR[oFKSzVyPUCuNFQyODVizszN MmnwV2FPT0WU
HEL NXrBXZRTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vnN2lEPTB;MD6wOFE1KM7:TR?= MknwV2FPT0WU
SW872 M2DYcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVL0UXQxUUN3ME2wMlA1OjFizszN M{DRenNCVkeHUh?=
DU-4475 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzZZ2pEUUN3ME2wMlA1OjR2IN88US=> MoC3V2FPT0WU
IST-SL2 NFztdmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1W4Z2lEPTB;MD6wOFI4PSEQvF2= NITne4tUSU6JRWK=
NCI-H82 M37RRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vHfWlEPTB;MD6wOFMxPyEQvF2= MkXOV2FPT0WU
LC4-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTBwMESzOVEh|ryP Mny5V2FPT0WU
HDLM-2 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7MeopUUUN3ME2wMlA1Ozl{IN88US=> M4LqO3NCVkeHUh?=
MMAC-SF NVe4OJRNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHwTI1KSzVyPUCuNFQ2OzRizszN NUHORZllW0GQR1XS
L-540 NYTmbGJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\uUnRHUUN3ME2wMlA1PjN7IN88US=> MoL2V2FPT0WU
MZ2-MEL MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TL[GlEPTB;MD6wOFc1OiEQvF2= NHXEV5JUSU6JRWK=
LU-134-A Mmi3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTBwMES3O|Mh|ryP NXrLfnpEW0GQR1XS
UACC-257 MnzHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFGze3hKSzVyPUCuNFQ5PDlizszN NUTkO3dyW0GQR1XS
NCI-H1581 NILRSI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PLT2lEPTB;MD6wOFk2OyEQvF2= MWnTRW5ITVJ?
NB17 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7hSG0yUUN3ME2wMlA1QTd7IN88US=> NHvpbnFUSU6JRWK=
SBC-1 M1[0Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTBwMEWwOFIh|ryP M1iwSnNCVkeHUh?=
TALL-1 NXXVXWpwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFu2R2dKSzVyPUCuNFUxPDVizszN MkfZV2FPT0WU
NCI-H1304 NEGyRXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjiZmNKSzVyPUCuNFUzODhizszN NXWwUZppW0GQR1XS
NEC8 NVTuWVhVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\XU|lKSzVyPUCuNFUzQDZizszN MmT0V2FPT0WU
CAL-148 M4XQR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvNO|AzUUN3ME2wMlA2PDN7IN88US=> MknzV2FPT0WU
CGTH-W-1 NVPwNpp1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHobHlyUUN3ME2wMlA2PDR7IN88US=> NHfNc|JUSU6JRWK=
NCI-H889 NIDBPHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\WTWM2OD1yLkC1OVkzKM7:TR?= NIDsdndUSU6JRWK=
GR-ST NGjodHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\CTWM2OD1yLkC1OlIyKM7:TR?= MljPV2FPT0WU
KARPAS-422 NYjFOYJkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTBcY1FUUN3ME2wMlA2PjVizszN M17IXnNCVkeHUh?=
RPMI-8866 M1zuZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlT0TWM2OD1yLkC1O|EzKM7:TR?= NX21TJZZW0GQR1XS
SCLC-21H M3XWT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rIOGlEPTB;MD6wOVg5PCEQvF2= Mk\4V2FPT0WU
COR-L88 NYTwdGhrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTBwMEW5Nlch|ryP NH\xOItUSU6JRWK=
LU-139 NEXoR49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPhNIJKSzVyPUCuNFU6QDZizszN NVTrNG1KW0GQR1XS
SF126 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzITWM2OD1yLkC2NVM{KM7:TR?= M3\Ed3NCVkeHUh?=
NCI-H1882 Ml;US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTBwME[0NlQh|ryP NU\PbXFIW0GQR1XS
EW-24 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHvTnJMUUN3ME2wMlA3PDh|IN88US=> M1Lad3NCVkeHUh?=
CP67-MEL Mon3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTRSmdxUUN3ME2wMlA3QDFizszN NHHrNmpUSU6JRWK=
DG-75 MlPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfVdoV[UUN3ME2wMlA3QDl7IN88US=> M4XjcnNCVkeHUh?=
LOXIMVI MkjSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITDe49KSzVyPUCuNFcxOjhizszN NVz0eWozW0GQR1XS
HH M13M[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LTXmlEPTB;MD6wO|E2PyEQvF2= M2jVVnNCVkeHUh?=
K5 M3TYW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF[4b45KSzVyPUCuNFczOjZizszN NXLDXos3W0GQR1XS
EC-GI-10 NUfyfotNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkGxTWM2OD1yLkC3NlU4KM7:TR?= NFnCR3BUSU6JRWK=
SK-N-DZ M1\0Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoL2TWM2OD1yLkC3N|A4KM7:TR?= M2\hWXNCVkeHUh?=
A3-KAW MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYC0ZppQUUN3ME2wMlA4OzVzIN88US=> NYTIWG91W0GQR1XS
MLMA NHjvU5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVG2eJRIUUN3ME2wMlA4PDZ3IN88US=> NF;Tb5hUSU6JRWK=
LB996-RCC MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLJTWM2OD1yLkC3O|A4KM7:TR?= MnjDV2FPT0WU
OS-RC-2 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTBwMEe3OFgh|ryP MX\TRW5ITVJ?
CTB-1 M1zISmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjvPHhvUUN3ME2wMlA4QDFizszN MYjTRW5ITVJ?
IST-MES1 NV;W[lVYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzw[2hKSzVyPUCuNFc6OTJizszN NYfUXHU1W0GQR1XS
LS-1034 MmK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTBwMEiwN|Uh|ryP MmWwV2FPT0WU
HT MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1juO2lEPTB;MD6wPFA5PiEQvF2= MXvTRW5ITVJ?
NCI-H2141 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETxW3VKSzVyPUCuNFgyKM7:TR?= M4HjSnNCVkeHUh?=
LB2518-MEL NH3zO3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1exVmlEPTB;MD6wPFE1OSEQvF2= NUmyWWN5W0GQR1XS
GI-ME-N M4XQd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTBwMEi0OVIh|ryP NILRVZVUSU6JRWK=
TGW M3H1cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTBwMEi2NFch|ryP MUHTRW5ITVJ?
SK-NEP-1 NIO1S3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLuT|FzUUN3ME2wMlA5PjRzIN88US=> MYnTRW5ITVJ?
NOMO-1 NVTUSJV5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XBN2lEPTB;MD6wPVI4PSEQvF2= NWfXSFV6W0GQR1XS
ES6 MmrvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;ZbFF[UUN3ME2wMlA6PTh7IN88US=> NWXqNZFxW0GQR1XS
NCI-H209 NVn3NpVCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInVb3ZKSzVyPUCuNFk4QDZizszN MVvTRW5ITVJ?
GAK NGDCVHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljyTWM2OD1yLkGwNVYh|ryP MkK4V2FPT0WU
BC-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\NOGhKSzVyPUCuNVA{PjFizszN M4H2fXNCVkeHUh?=
KLE NVvMbHZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DGWGlEPTB;MD6xNFQ1OyEQvF2= NFPPWYlUSU6JRWK=
EW-3 NX3pXms1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWCw[5dQUUN3ME2wMlExQThizszN NXnhO4w1W0GQR1XS
NKM-1 NFjT[JBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTBwMUGxJO69VQ>? MWnTRW5ITVJ?
D-336MG NV\2[nV7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\1NlBIUUN3ME2wMlEyOjR2IN88US=> MVvTRW5ITVJ?
NB69 MonpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17neWlEPTB;MD6xNVMxOSEQvF2= NH\ZVFFUSU6JRWK=
D-263MG NEDF[3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7sV3RKSzVyPUCuNVE4OTJizszN MoCwV2FPT0WU
KP-N-YS NF7MVoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nnU2lEPTB;MD6xNlI6OSEQvF2= M4C4[nNCVkeHUh?=
NCI-H1155 NWnSTWtET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXWTWM2OD1yLkGyOVU5KM7:TR?= MYDTRW5ITVJ?
BOKU M{ft[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;1XVFKSzVyPUCuNVI2PzlizszN NFSyVYZUSU6JRWK=
LAMA-84 M4C1ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTBwMUK5PUDPxE1? M37Fd3NCVkeHUh?=
Raji Ml3vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHScFBKSzVyPUCuNVMyOTdizszN NELu[VNUSU6JRWK=
LU-65 NXz4RnExT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTBwMUOzNFch|ryP MnfEV2FPT0WU
NCI-H187 MlXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlf5TWM2OD1yLkGzPVI1KM7:TR?= M2PMV3NCVkeHUh?=
GCIY NYn2PFRDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHqXJFKSzVyPUCuNVQ6ODFizszN MVnTRW5ITVJ?
NCI-H2107 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jtfmlEPTB;MD6xOVA5KM7:TR?= MULTRW5ITVJ?
NCI-H1522 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;D[mZKSzVyPUCuNVUzPjZizszN NIn4VpRUSU6JRWK=
NB6 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;4UYdKSzVyPUCuNVU3OjNizszN NEO0eIZUSU6JRWK=
EM-2 NIj5ZYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHnTWM2OD1yLkG1O|A3KM7:TR?= NGriTopUSU6JRWK=
HCC2218 M3zmOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIi5S5ZKSzVyPUCuNVU6QCEQvF2= M2nPTHNCVkeHUh?=
NCI-H748 NXSxTGZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYK1V4lQUUN3ME2wMlE3Ozd4IN88US=> NXvNcpp{W0GQR1XS
MS-1 NVvK[4RST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWe1PVVYUUN3ME2wMlE3PTN5IN88US=> MYjTRW5ITVJ?
NB5 M3Xpcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzpTWM2OD1yLkG2OVk4KM7:TR?= M1;jZ3NCVkeHUh?=
OMC-1 MnXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDTTWM2OD1yLkG2Olg5KM7:TR?= MlK4V2FPT0WU
NCI-H345 NVnlcXpIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYW4N2VbUUN3ME2wMlE3QTJ6IN88US=> Mlq0V2FPT0WU
L-428 NHnxdpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkixTWM2OD1yLkG2PVQ2KM7:TR?= NUDl[nA5W0GQR1XS
SCH MlzkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTBwMUi2PFUh|ryP MYrTRW5ITVJ?
NCI-H1417 NVrWW4tiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3vWXR[UUN3ME2wMlE6OjJ5IN88US=> MnvHV2FPT0WU
COLO-320-HSR NXfRendNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjiW5dXUUN3ME2wMlE6PTN{IN88US=> NXXIV5hUW0GQR1XS
BT-474 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTBwMkC4PVIh|ryP MVnTRW5ITVJ?
GDM-1 MmWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLZclA5UUN3ME2wMlIyQTdzIN88US=> MVvTRW5ITVJ?
NCI-H2196 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlftTWM2OD1yLkKyNlM2KM7:TR?= NIfQeWdUSU6JRWK=
KP-N-RT-BM-1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvXO5hQUUN3ME2wMlIzOzR7IN88US=> MVPTRW5ITVJ?
KNS-81-FD NVSxXJhGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HWUWlEPTB;MD6yNlk2QCEQvF2= NXzqbVZJW0GQR1XS
COLO-668 NUDObpZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVT4[pBHUUN3ME2wMlI{Pjd3IN88US=> NWjQb41CW0GQR1XS
C2BBe1 MlLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVuyOHF6UUN3ME2wMlI3PzR5IN88US=> MWTTRW5ITVJ?
Ramos-2G6-4C10 NXXCOVVoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPETWM2OD1yLkK2PVU1KM7:TR?= NGS4XZNUSU6JRWK=
CAS-1 NUn5XXcyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTBwMkewPVYh|ryP MmHEV2FPT0WU
GOTO NGfkV|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3DOHd6UUN3ME2wMlI4QDl2IN88US=> MYPTRW5ITVJ?
LP-1 M1jnb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTqbJFGUUN3ME2wMlI5ODV5IN88US=> NWr0eGRFW0GQR1XS
NCI-SNU-1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13Xc2lEPTB;MD6yPVQzOiEQvF2= NXvUZYd7W0GQR1XS
EB-3 M{W3S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDaTWM2OD1yLkK5PVc6KM7:TR?= Mk\rV2FPT0WU
MHH-NB-11 NWPVVG93T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWexS405UUN3ME2wMlMxPDB{IN88US=> NG\QSGFUSU6JRWK=
SK-N-FI MmjPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHZTWM2OD1yLkOxOlkzKM7:TR?= NW\0TW1XW0GQR1XS
HCC2157 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHNTWM2OD1yLkOzPVE{KM7:TR?= NUC1OoJWW0GQR1XS
SIMA MnzCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\ubo5KSzVyPUCuN|Q2QDFizszN NGTyUm9USU6JRWK=
MDA-MB-134-VI NH\3RmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTBwM{[5Nlgh|ryP NFf2NWRUSU6JRWK=
NCI-H1694 MnK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWmwNlE{UUN3ME2wMlM4KM7:TR?= MVLTRW5ITVJ?
EHEB NV\VcmRtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fNW2lEPTB;MD6zPVA5PSEQvF2= NHHUWndUSU6JRWK=
U-266 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTBwM{m4OFYh|ryP MYHTRW5ITVJ?
LC-1F NWXlUmE3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlX6TWM2OD1yLkSzO|Y2KM7:TR?= NFnQNoJUSU6JRWK=
SHP-77 NXrXVppvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnw[ppKSzVyPUCuOFc5PTVizszN M4jOd3NCVkeHUh?=
LS-513 NXjzO3R5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljtTWM2OD1yLkS5N|A4KM7:TR?= M2rNb3NCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo試験 The inhibition rations of Paclitaxel alone on BC-V and BC-ER tumors are 49.78% and 51.23%, respectively. Treatment of six cycles of 20 mg/kg Paclitaxel significantly reduces the percentages of Ki-67-positive cells to 20.4% in BC-V tumors and 25.1% in BC-ER tumors, respectively. [4]
臨床試験 Paclitaxel has entered in a Phase III clinical trial for the treatment of tubular breast cancer stage II, mucinous breast cancer stage II, breast cancer female NOS and invasive ductal breast cancer.
特集

プロトコル (参考用のみ)

細胞アッセイ: [1]

細胞株 Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs
濃度 0.1-100 pM
反応時間 72 hours
実験の流れ Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs), human mammary epithelial cells (HMEpCs), human prostate epithelial cells (PrEpCs) and human umbilical artery smooth muscle cells (UASMCs) are cultured. Cell proliferations are performed in 96-well plates using cells between passages 6 and 12. Cells are seeded at 3000–5000 cells/well and allowed to attach for 4 hours. Paclitaxel, diluted in culture medium, is added in quadruplicate wells and the cells ae incubated for 3 days before MTS reagents are added to quantitate the live cells in each well.

動物実験: [4]

動物モデル Female, 20-22 g homozygous nude athymic mice with BC-V and BC-ER tumors
製剤 Control
投薬量 20 mg/kg
投与方法 Administered via i.v.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download Paclitaxel SDF
分子量 853.91
化学式

C47H51NO14

CAS No. 33069-62-4
保管 2年-20℃
6月-80℃in solvent
別名 NSC 125973
溶解度 (25°C) * In vitro DMSO 171 mg/mL (200.25 mM)
エタノール 18 mg/mL (21.07 mM)
<1 mg/mL (<1 mM)
In vivo 1% DMSO/30% polyethylene glycol/1% Tween 80 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βS)-

カスタマーフィードバック (2)


Click to enlarge
Rating
Source , , ACS Appl Mater Interfaces, 2015, 7(14): 7584-98. Paclitaxel purchased from Selleck
Method Confocal Laser Scanning Microscopy Study
Cell Lines HeLa cells
Concentrations 5 μM
Incubation Time 24 h
Results From the figure, it was clear that interestingly α-TOS-Paclitaxel-NP induced highest PARP expression compared to α-TOS-CDDP-NP and α-TOS-Dox-NP.

Click to enlarge
Rating
Source RSC Adv , 2011, 1, 884-892. Paclitaxel purchased from Selleck
Method Microscope image
Cell Lines U937 cells
Concentrations
Incubation Time 24 h
Results The ODS-treated cells in Fig. b looked identical to the untreated cells in Fig. a with a similar rate of natural cell death of less than 3%. When Taxol microcrystals are added to the cell culture (the standard way that Taxol is released into biological systems), decreased cell proliferation rate, pronounced swelling and vacuolization are observed, as shown in Fig. c.

文献中の引用 (14)

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related 微小管関連 阻害剤

  • TAI-1

    TAI-1 is a potent and specific Hec1 inhibitor, which disrupts Hec1-Nek2 protein interaction.

  • Docetaxel Trihydrate

    Docetaxel, an analog of taxol, is an inhibitor of depolymerisation of microtubules by binding to stabilized microtubules.

  • Combretastatin A4

    Combretastatin A4 is a microtubule-targeting agent that binds β-tubulin with Kd of 0.4 μM.Phase 3.

  • FRAX597

    FRAX597 is a potent, ATP-competitive inhibitor of group I PAKs with IC50 of 8 nM, 13 nM, and 19 nM for PAK1, PAK2, and PAK3, respectively.

  • Docetaxel

    Docetaxel is an microtubule disassembly inhibitor with IC50 of a range of 0.31-100 ηM.

  • Vincristine

    Vincristine is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32 μM.

  • Nocodazole

    Nocodazoleは反微小管薬品で、 ABL、 ABL(E255K) 、ABL(T315I)に作用すると 、 IC50 が それぞれ0.21 μM、 0.53 μM 、 0.64 μMになる。

  • Vinblastine

    Vinblastine inhibits microtubule formation and supresses nAChR activity with IC50 of 8.9 μM.

  • Vinorelbine Tartrate

    Vinorelbine Tartrate is a semi-synthetic vinca alkaloid, and inhibits mitosis through interaction with tubulin.

最近チェックしたアイテム

Tags: Paclitaxelを買う | Paclitaxel供給者 | Paclitaxelを購入する | Paclitaxel費用 | Paclitaxel生産者 | オーダーPaclitaxel | Paclitaxel代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
お問い合わせ